Who are NuCana plc's main suppliers?

NuCana plc (NCNA) key suppliers include: EUROPEAN-UNION, INDIA, ORANY, ORANY, Virax Biolabs Group Limited. View the full supplier network at chainsifter.com/chain/NCNA.

Who are NuCana plc's major customers?

NuCana plc (NCNA) key customers include: ORANY, ORANY, CARDIFF-PROTIDES-LTD, NUCANA-BIOMED-TRUSTEE-COMPANY-LIMITED, NUCANA-LIMITED and 3 more. View the full customer network at chainsifter.com/chain/NCNA.

What sector is NuCana plc in?

NuCana plc (NCNA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

NuCana plc Supplier List (NCNA): 5 Verified Suppliers

5Suppliers

8Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

NuCana plc (NCNA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

2Distinct source URLs

4High confidence

0.728Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

NuCana plc Suppliers

Ticker	Name	Confidence	Evidence
EUROPEAN-UNION	EUROPEAN-UNION	90%	we source our active pharmaceutical ingredient, or API, and other raw materials and our research and development, manufacturing, consulting and other services worldwide, including from the European Union
INDIA	INDIA	90%	we source our active pharmaceutical ingredient, or API, and other raw materials and our research and development, manufacturing, consulting and other services worldwide, including from India
ORANY	ORANY	72%	log standards of care. We are working to identify and quantify key biomarkers relevant to NUC-7738 and NUC-3373, as well as to assess their predictive nature with regard to treatment. In addition, su…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from NCNA graph: log standards of care. We are working to identify and quantify key biomarkers relevant to NUC-7738 and NUC-3373, as …
VRAX	Virax Biolabs Group Limited	72%	Reciprocal relationship from VRAX graph: Reciprocal relationship from NCNA graph: Reciprocal relationship from VRAX graph: regular healthcare consulting are still hindrances in some regions, especial…

NuCana plc Customers

Ticker	Name	Confidence	Evidence
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from NCNA graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from NCNA graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	log standards of care. We are working to identify and quantify key biomarkers relevant to NUC-7738 and NUC-3373, as well as to assess their predictive nature with regard to treatment. In addition, su…
CARDIFF-PROTIDES-LTD	CARDIFF-PROTIDES-LTD	62%	ucleoside analog standards of care. We are working to identify and quantify key biomarkers relevant to NUC-7738 and NUC-3373, as well as to assess their predictive nature with regard to treatment. In…
NUCANA-BIOMED-TRUSTEE-COMPANY-LIMITED	NUCANA-BIOMED-TRUSTEE-COMPANY-LIMITED	62%	our product candidates may not be considered medically necessary or cost-effective by payors. Further, a payor’s decision to provide coverage for a product does not imply that an adequate reimburseme…
NUCANA-LIMITED	NUCANA-LIMITED	62%	our product candidates may not be considered medically necessary or cost-effective by payors. Further, a payor’s decision to provide coverage for a product does not imply that an adequate reimburseme…
SILVERGATE-CAPITAL-CORP	SILVERGATE-CAPITAL-CORP	62%	d. In this regard, counterparties to financial institution credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impac…
UK-LTD	UK-LTD	62%	it was primarily attributable to a decrease in our eligible research and development expenses. Comparison of Year Ended December 31, 2023 and 2024 The discussion of our operating results for the year…
UNIVERSITY-COLLEGE-CARDIFF-CONSULTANTS-LTD	UNIVERSITY-COLLEGE-CARDIFF-CONSULTANTS-LTD	62%	ucleoside analog standards of care. We are working to identify and quantify key biomarkers relevant to NUC-7738 and NUC-3373, as well as to assess their predictive nature with regard to treatment. In…

NuCana plc Debt Obligations

Instrument	Description	Confidence	Evidence
NCNA-DEBT	Debt stack $909,323	90%	Market cache reports total debt of $909,323.

NuCana plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for NuCana plc.

NuCana plc Ownership

Holder	Name	Confidence	Evidence
NCNA-OWNER-DANSKE-BANK-A-S	DANSKE BANK A/S	90%	13F overlay lists DANSKE BANK A/S as top holder; 1 tracked holders.

NuCana plc Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
QGEN	Qiagen N.V.	100.00	2
ABT	Abbott Laboratories	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
AMZE	Amaze Holdings, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CHUC	Charlie's Holdings, Inc.	50.00	2
CLNE	Clean Energy Fuels Corp.	50.00	2
FENC	Fennec Pharmaceuticals Inc.	50.00	2
EQR	Equity Residential	50.00	2
CNOB	ConnectOne Bancorp, Inc.	50.00	2
ESS	Essex Property Trust, Inc.	50.00	2
DWTX	Dogwood Therapeutics, Inc.	50.00	2
ED	Consolidated Edison, Inc.	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
BSBK	Bogota Financial Corp.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2

NuCana plc Supply Chain